BeyondSpring sells majority stake in China unit to Biolin to fund DUBLIN-4 trial enrollment

• BeyondSpring agreed to sell BeyondSpring Ltd., which indirectly holds a majority stake in its Chinese subsidiary Bulin, to Biolin Investment.
• Biolin’s non-cash consideration is funding DUBLIN-4 clinical development activities in China, expected to cover about 221 patients.
• The China enrollment is expected to represent about 50% of the planned 442-patient global Phase 3 DUBLIN-4 trial.
• BeyondSpring will retain global rights to Plinabulin outside Greater China, with access to clinical data generated from the China trial portion.
• The deal is intended to reduce BeyondSpring’s cash requirements for DUBLIN-4 ahead of the prespecified interim analysis at 221 PFS events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290701PRIMZONEFULLFEED9835484) on September 29, 2026, and is solely responsible for the information contained therein.